Free tool
FAERS Monitor: Rhopressa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 208254 or its brand name (Rhopressa, Netarsudil Mesylate). Reports on generic versions are filed under their own applications.
Reports
1,971
Serious
434
22% of reports
Hospitalization
105
Death reported
63
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- conjunctival hyperaemia246
- vision blurred165
- ocular hyperaemia162
- off label use158
- eye pain149
- eye irritation123
- product dose omission issue98
- corneal oedema95
- intraocular pressure increased95
- lacrimation increased94
- visual acuity reduced89
- drug ineffective79
- eye pruritus70
- cornea verticillata60
- headache57
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2017 | 1 |
| 2018 | 145 |
| 2019 | 470 |
| 2020 | 253 |
| 2021 | 111 |
| 2022 | 137 |
| 2023 | 244 |
| 2024 | 210 |
| 2025 | 227 |
| 2026 | 173 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,188 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cornea verticillataSignal | 60 | 2626.5 | 1987.1 | 124,292 |
| conjunctival hyperaemiaSignal | 246 | 790.9 | 700.3 | 179,995 |
| corneal oedemaSignal | 95 | 472.4 | 386.5 | 42,349 |
| intraocular pressure increasedSignal | 95 | 79.9 | 65.6 | 7,274 |
| ocular hyperaemiaSignal | 162 | 36.5 | 31.5 | 5,559 |
| lacrimation increasedSignal | 94 | 33.3 | 27.3 | 2,908 |
| visual acuity reducedSignal | 89 | 28.7 | 23.4 | 2,347 |
| eye painSignal | 149 | 28.3 | 24.2 | 3,890 |
| eye irritationSignal | 123 | 22.9 | 19.3 | 2,550 |
| eye pruritusSignal | 70 | 22.3 | 17.7 | 1,401 |
| vision blurredSignal | 165 | 12.8 | 11.1 | 1,799 |
| product dose omission issueSignal | 98 | 3.6 | 2.9 | 180 |
| off label use | 158 | 1.9 | 1.7 | 72 |
| headache | 57 | 1.0 | 0.8 | 0 |
| drug ineffective | 79 | 0.6 | 0.5 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.